Peter Lawson

Stock Analyst at Barclays

(2.10)
# 1,574
Out of 4,433 analysts
78
Total ratings
41.54%
Success rate
-6.8%
Average return

30 Stocks

MacroGenics
May 10, 2024
Maintains: Overweight
Price Target: $25$14
Current: $4.37
Upside: +220.73%
Relay Therapeutics
May 10, 2024
Upgrades: Overweight
Price Target: $15
Current: $6.64
Upside: +125.90%
Blueprint Medicines
May 3, 2024
Maintains: Equal-Weight
Price Target: $70$75
Current: $104.96
Upside: -28.54%
Deciphera Pharmaceuticals
Apr 30, 2024
Upgrades: Equal-Weight
Price Target: $9$26
Current: $25.46
Upside: +2.12%
Exelixis
Apr 11, 2024
Downgrades: Equal-Weight
Price Target: $25
Current: $20.91
Upside: +19.56%
TScan Therapeutics
Mar 7, 2024
Maintains: Overweight
Price Target: $7$9
Current: $8.98
Upside: +0.22%
Arvinas
Feb 29, 2024
Maintains: Overweight
Price Target: $26$60
Current: $32.68
Upside: +83.60%
Iovance Biotherapeutics
Feb 29, 2024
Maintains: Overweight
Price Target: $18$22
Current: $10.24
Upside: +114.84%
SpringWorks Therapeutics
Feb 29, 2024
Maintains: Overweight
Price Target: $47$63
Current: $44.84
Upside: +40.50%
Fate Therapeutics
Feb 27, 2024
Maintains: Overweight
Price Target: $6$10
Current: $3.90
Upside: +156.41%
Replimune Group
Dec 6, 2023
Maintains: Overweight
Price Target: $50$13
Current: $6.44
Upside: +101.86%
Exscientia
Oct 17, 2023
Maintains: Overweight
Price Target: $12$10
Current: $5.20
Upside: +92.31%
Adaptimmune Therapeutics
Aug 10, 2023
Maintains: Underweight
Price Target: $2$1
Current: $1.11
Upside: -9.91%
Prelude Therapeutics
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7$5
Current: $4.00
Upside: +25.00%
Syndax Pharmaceuticals
Jul 26, 2023
Maintains: Overweight
Price Target: $31$34
Current: $20.29
Upside: +67.57%
Biomea Fusion
May 12, 2023
Initiates: Overweight
Price Target: $50
Current: $12.24
Upside: +308.50%
Nurix Therapeutics
Mar 9, 2023
Initiates: Overweight
Price Target: $20
Current: $16.59
Upside: +20.55%
Arcus Biosciences
Dec 21, 2022
Maintains: Overweight
Price Target: $60$35
Current: $16.90
Upside: +107.10%
Immunocore Holdings
Nov 30, 2022
Initiates: Overweight
Price Target: $80
Current: $53.29
Upside: +50.12%
NexImmune
Aug 16, 2022
Maintains: Overweight
Price Target: $175$50
Current: $3.34
Upside: +1,398.80%
Karyopharm Therapeutics
Aug 5, 2022
Maintains: Overweight
Price Target: $14$8
Current: $1.15
Upside: +595.65%
Bicycle Therapeutics
Jul 28, 2022
Initiates: Overweight
Price Target: $30
Current: $21.36
Upside: +40.45%
CytomX Therapeutics
Jul 7, 2022
Maintains: Overweight
Price Target: $7$3.5
Current: $1.89
Upside: +85.19%
Illumina
Aug 6, 2021
Maintains: Underweight
Price Target: n/a
Current: $111.07
Upside: -
Agios Pharmaceuticals
Oct 22, 2020
Upgrades: Overweight
Price Target: n/a
Current: $34.34
Upside: -
Xencor
Mar 4, 2020
Initiates: Underweight
Price Target: n/a
Current: $23.03
Upside: -
Nektar Therapeutics
Mar 4, 2020
Initiates: Overweight
Price Target: n/a
Current: $1.76
Upside: -
Editas Medicine
Jan 23, 2018
Upgrades: Buy
Price Target: n/a
Current: $5.62
Upside: -
CRISPR Therapeutics AG
Jan 23, 2018
Upgrades: Buy
Price Target: n/a
Current: $56.22
Upside: -
Affimed
Jul 14, 2017
Initiates: Buy
Price Target: $70
Current: $5.25
Upside: +1,233.33%